Professor of Medicine, Harvard Medical School and Director, Ludwig Center at Dana-Farber/Harvard
Oncology
Dr. George D. Demetri, MD
|
|
Give Review
George D. Demetri is an expert in the field of Oncology. He went to Stanford University School of Medicine. Stanford University School of Medicine is a top medical university. Stanford University School of Medicine has a rank of 2 in research and a 25 in primary care He received awards:"Fellow (FASCO)", "Whos Who in Medicine and Healthcare" and "Super Doctor". Dr. George D. Demetri is also a published doctor. He has 101 publication published. The most recent publication is: Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Doctor George D. Demetri, MD accepts all Medicare patients.
Publications
- Preclinical activity of selinexor, an inhibitor of XPO1, in Sarcoma.
- Eribulin versus dacarbazine in previously treated patients with advanced lipoSarcoma or leiomyoSarcoma: a randomised, open-label, multicentre, phase 3 trial.
- A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.
- Phase 1 study of Oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
- c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in Soft tissue sarcomas.
- Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human LipoSarcoma In Vitro and In Vivo.
- Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyoSarcoma.
- Dystrophin is a tumor suppressor in human Cancers with myogenic programs.
- Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care.
- Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial.
- International expert opinion on patient-tailored management of Soft tissue sarcomas.
- Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imati...
- Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyoSarcomas expressing estrogen and/or progesterone receptors.
- A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas.
- Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic Sarcomas in pa...
- Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor: ACOSOG Z9000 (Alliance) Intergroup Phase 2 Trial.
- Clinical outcomes and safety with trabectedin therapy in patients with advanced Soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide ex...
- Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal Tumors.
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomi...
- Regorafenib Induces Rapid and Reversible Changes in Plasma Nitric Oxide and Endothelin-1.
- Imaging features of bone metastases in patients with gastrointestinal stromal Tumors.
- Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib F...
- Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial.
- Tivantinib (ARQ 197), a selective inhibitor of mesenchymal-epithelial transition factor, in patients with microphthalmia transcription factor-associated Tumors: Result...
- A murine lung Cancer co-clinical trial identifies genetic modifiers of therapeutic response.
- First-line treatment of metastatic or locally advanced unresectable Soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase...
- Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Re...
- NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement.
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas.
- Aberrant AKT activation drives well-differentiated lipoSarcoma.
- Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced Soft tissue sarcomas.
- A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid Tumors treated in phase II clinical trials.
- Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal Tumors.
- The evolution of a revolutionary class: extending benefits of tyrosine kinase inhibitors--introduction.
- Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid Tumors.
- Strong expression of IGF1R in pediatric gastrointestinal stromal Tumors without IGF1R genomic amplification.
- Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
- Disease state awareness in Sarcoma.
- NCCN Task Force report: update on the management of patients with gastrointestinal stromal Tumors.
- Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell Tumors: targeting the pathogenic activation of mTORC1 in Tumors.
- Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate.
- Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and Soft tissue damage.
- Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid Tumors.
- A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal Tumors.
- Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.
- Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
- Efficacy and safety of trabectedin in patients with advanced or metastatic lipoSarcoma or leiomyoSarcoma after failure of prior anthracyclines and ifosfamide: results ...
- Gastrointestinal stromal Tumors II: medical oncology and tumor response assessment.
- Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
- Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal Tumors.
- Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor Sarcomas.
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
- KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.
- Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GIST.
- Small molecule tyrosine kinase inhibitor and depression.
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early resul...
- Imatinib targeting of KIT-mutant oncoprotein in melanoma.
- Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced Soft tissue sarcoma.
- Primary and Secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
- Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal st...
- Major response to imatinib mesylate in KIT-mutated melanoma.
- A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
- Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal Tumors expre...
- Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stro...
- Structural reengineering of imatinib to decrease cardiac risk in Cancer therapy.
- CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
- LeiomyoSarcoma of the inferior vena cava: survival after aggressive management.
- Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal Tumors.
- Gemcitabine and vinorelbine combination chemotherapy for patients with advanced Soft tissue sarcomas: results of a phase II trial.
- High-throughput oncogene mutation profiling in human Cancer.
- Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent Lung carcinomas.
- Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal Tumors.
- Molecular correlates of imatinib resistance in gastrointestinal stromal Tumors.
- Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
- Surgical management of advanced gastrointestinal stromal Tumors after treatment with targeted systemic therapy using kinase inhibitors.
- Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
- Cancer- and treatment-related Anemia.
- Update on new diagnostic and therapeutic approaches for Sarcomas.
- Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.
- Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred.
- Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal Tumors.
- Molecular and clinical analysis of locally advanced dermatofibroSarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
- Pharmacodynamic analysis of target inhibition and endothelial cell death in Tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or S...
- Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass.
- Phase II study of the antiangiogenic agent SU5416 in patients with advanced Soft tissue sarcomas.
- Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal Tumors (GISTs).
- Serum KIT and KIT ligand levels in patients with gastrointestinal stromal Tumors treated with imatinib.
- Gastrointestinal stromal Tumors (GISTs).
- Use of erythropoietin in Cancer patients: assessment of oncologists' practice patterns in the United States and other countries.
- Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
- Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteoSarcoma.
- Soft tissue sarcomas of adults: state of the translational science.
- Multicenter phase II study of oral bexarotene for patients with metastatic Breast cancer.
- Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primar...
- PDGFRA activating mutations in gastrointestinal stromal Tumors.
- Current management of metastatic gastrointestinal stromal tumor: a case report.
- Challenges in the development of platelet growth factors: low expectations for low counts.
- Targeting the molecular pathophysiology of gastrointestinal stromal Tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
- Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal Tumors.
- A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal Cancer.
Schools
Stanford University School Of Medicine
University of Washington
Dana FarberHarvard
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
Conditions Treated
- Anemia
- Breast Cancer
- Leukocytosis
- Liver Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Fellow (FASCO)
- Whos Who in Medicine and Healthcare
- Super Doctor
Education
-
University of Washington -
Stanford University School of Medicine
Hospital
-
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1841267093 |
| Last Name Of The Provider | DEMETRI |
| First Name Of The Provider | GEORGE |
| View All |
Similar Doctors
|
|
Dr. Robert L. Schlossman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert H. Gottlieb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas J. Schuetz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Glenn Dranoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jack S. Leitner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William C. Hahn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vincent T. Ho, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harold J. Burstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven P. Treon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles Rosenbaum, MD
This Doctor is OpenDoctor Recommended.
|